Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.
Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.
Dr. Heather Wakelee, Stanford University Medical Center, discusses the purpose of adjuvant chemotherapy, and which patients benefit most from it.
Transcript One of the important points about patients with advanced lung cancer is that 30-40% of patients will develop bone metastases. I think it’s...
Transcript I think we know a lot now about how to treat patients with advanced stage lung cancer, and there are several things that we factor in when...
Drs. Nate Pennell, Mary Pinder, and Jack West discuss the START trial of L-BLP-25 (tecemotide) immunotherapy in locally advanced NSCLC. [powerpress]
One of the highest profile clinical studies over the last few years has been the START trial of Stimuvax, also known as L-BLP-25 or tecemotide, an...
Dr. Rosalyn Juergens, McMaster University, reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results...
Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of...
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes which patients with advanced non-small cell lung cancer he would recommend getting a...
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.
Dr. Greg Riely from MSKCC provides an introduction to the epidermal growth factor receptor (EGFR), what an EGFR mutation means, and which patients are more likely to have them.
Memorial Sloan-Kettering Cancer Center medical oncologist Dr. Greg Riely explains how testing for specific mutations in patients with advanced NSCLC can guide prognosis and treatment recommendations.
After having had further discussions with colleagues about the data and the challenges in interpreting the optimal treatment in this setting, I am inclined to soften my view that Taxotere is quite likely to be the superior second line therapy for most patients...
Dr. Vivek Mehta, radiation oncologist, reviews the basic principles and treatment approach for limited stage small cell lung cancer, which combines chest radiation with concurrent chemotherapy.
Why radiate a perfectly good brain? Dr. Vivek Mehta, radiation oncologist, discusses the possible role for prophylactic cranial irradiation (PCI) for extensive stage small cell lung cancer (SCLC) to decrease risk of brain metastases and improve survival.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.